| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2004005474A3 A robust, inducible cardiac preferred expression system for transgenesis |
| 06/24/2004 | WO2003103583A3 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003057200A3 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 06/24/2004 | WO2003051841A3 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 06/24/2004 | WO2003049686A3 Stabilization of hypoxia inducible factor (hif) alpha |
| 06/24/2004 | WO2003018044A8 New drug |
| 06/24/2004 | WO2003014309A3 Interleukin-1 receptors in the treatment of diseases |
| 06/24/2004 | WO2003008560A8 A novel g protein-coupled receptor, gave8 |
| 06/24/2004 | US20040122235 such as N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; for treating diseases in which increasing glucokinase activity is beneficial (diabetes) |
| 06/24/2004 | US20040122218 Pyrrolopyridine potassium channel openers |
| 06/24/2004 | US20040122125 Lactone compounds as novel photoinitiators |
| 06/24/2004 | US20040122084 7-Methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.02,4. 05,7. 09,13]heptadec-1(17)-ene-11,16-dione derivatives; antitumor, -proliferative, -carcinogenic agents; viricides;DNA polymerase inhibitors; bactericides; solubility; stability; injections |
| 06/24/2004 | US20040122083 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin" |
| 06/24/2004 | US20040122077 Administering a statin drug in an amount to promote angiogenesis in the tissue, preferably in situations where the subject is not otherwise in need of the drug ; activating Akt (protein kinase B) in vascular endothelial cells in vitro and in vivo |
| 06/24/2004 | US20040122067 Treatment of chronic heart failure |
| 06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
| 06/24/2004 | US20040122049 heterocyclic derivatives containing N-substituted piperidine ring and an amide or urea group; useful for treating rheumatic arthritis |
| 06/24/2004 | US20040122047 Substituted tetrahydroisoquinolines |
| 06/24/2004 | US20040122044 Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations |
| 06/24/2004 | US20040122042 nitrogen containing heterocyclic compounds as chymase inhibitor together with ace enzyme inhibitor are effective for the treatment of hypertension and cardiac disease |
| 06/24/2004 | US20040122040 Bicyclic guanidine derivatives and therapeutic uses thereof |
| 06/24/2004 | US20040122039 Pyrazolo[1,5-a]pyridines and medicines containing the same |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122031 Thiazolidinedione and pharmaceutical composition comprising the same |
| 06/24/2004 | US20040122030 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide |
| 06/24/2004 | US20040122017 Melanin concentrating hormone (MCH) modulators; metabolic and eating disorders |
| 06/24/2004 | US20040122011 such as 3-[3-[N-isopropyl-N-(4-methoxyphenyl-sulfonyl)amino]-phenyl]-3-(3-pyridyl)-2(E)-propenohydroxamic acid; for treatment/prevention of neoplasia/inflammation; kits |
| 06/24/2004 | US20040122006 such as 7-[(2-aminophenyl)sulfanyl]-2H-1,4-benzoxazin-3(4H)-one; oxidation/reduction; deblocking/deprotectiing; cardiovascular disorders |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040122002 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 06/24/2004 | US20040122001 Pharmaceutical compounds |
| 06/24/2004 | US20040121997 20-hydroxyeicosatetraenoic acid production inhibitors |
| 06/24/2004 | US20040121993 for the reduction of cholesterol in blood, and treatment of fatty liver, hyperglycemia and diabetes |
| 06/24/2004 | US20040121981 Administering therapeutically effective amount of a compound which binds to a galectin |
| 06/24/2004 | US20040121979 Pharmaceutically active uridine esters |
| 06/24/2004 | US20040121962 Prodrugs of excitatory amino acids |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121345 Identification of a human n-terminal acetyltransferase gene |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040121008 Process for producing sustained release preparation |
| 06/24/2004 | US20040120999 Liposome containing remedy for vascular disease |
| 06/24/2004 | US20040120930 Administering mutant epithelial nitric oxide synthase with mutation at a position corresponding to an amino acid residue in a mammalian eNOS that is phosphorylated in mammalian cells; |
| 06/24/2004 | DE10257356A1 Fluorhaltige Aromaten Fluorine-containing aromatics |
| 06/24/2004 | CA2510610A1 Microtubule stabilisers for treating stenosis in stents |
| 06/24/2004 | CA2508715A1 Materials and methods relating to treatment of injury and disease to the central nervous system |
| 06/24/2004 | CA2508663A1 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases |
| 06/24/2004 | CA2508623A1 Benzomorpholine derivatives |
| 06/23/2004 | EP1431294A1 Vascular wall-selective acat inhibitor |
| 06/23/2004 | EP1431293A1 Water-soluble phenylpyridazine derivatives and drugs containing the same |
| 06/23/2004 | EP1431285A1 Reverse hydroxamic acid derivatives |
| 06/23/2004 | EP1431279A2 Fluoride containing aromatic compounds |
| 06/23/2004 | EP1430898A1 Receptor antagonist |
| 06/23/2004 | EP1430890A1 Thrombus/thrombogenesis inhibitors |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430140A2 Isoform-selective inhibitors and activators of pde3 cyclic |
| 06/23/2004 | EP1430126A1 Dna sequences for human angiogenesis genes |
| 06/23/2004 | EP1430057A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives |
| 06/23/2004 | EP1430056A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 06/23/2004 | EP1430053A1 Chemical compounds |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430045A1 Pyrane derivatives as both ace- and nep-inhibitors |
| 06/23/2004 | EP1430043A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 06/23/2004 | EP1430042A2 Bicyclic heterocycles as rxr ligands |
| 06/23/2004 | EP1430041A2 Novel sulfonic acid derivatives |
| 06/23/2004 | EP1430040A1 Benzothiazepine derivatives |
| 06/23/2004 | EP1430039A2 Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis |
| 06/23/2004 | EP1430032A2 Substituted amides for the treatment of neurological disorders |
| 06/23/2004 | EP1430031A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 06/23/2004 | EP1430027A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 06/23/2004 | EP1430020A1 Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them |
| 06/23/2004 | EP1429819A1 Optimized dosing for drug coated stents |
| 06/23/2004 | EP1429784A2 High throughput screening assays using fatty acid synthetic enzymes |
| 06/23/2004 | EP1429782A1 Modulation of vitamin storage |
| 06/23/2004 | EP1429781A2 Composition comprising nanoparticulate spironolactone |
| 06/23/2004 | EP1429779A2 Androstanes as androgen receptor modulators |
| 06/23/2004 | EP1429777A1 Ophthalmologic treatment methods using selective inos inhibitors |
| 06/23/2004 | EP1429775A1 Methods of treating pulmonary disease |
| 06/23/2004 | EP1429773A1 Process for making substituted pyrazoles |
| 06/23/2004 | EP1429767A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 06/23/2004 | EP1429762A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| 06/23/2004 | EP1429761A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 06/23/2004 | EP1429760A1 Novel combination |
| 06/23/2004 | EP1429752A1 Neuroprotective treatment methods using selective inos inhibitors |
| 06/23/2004 | EP1429751A1 Salicylic acid salts, methods for the production and use thereof as medicaments |
| 06/23/2004 | EP1429729A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin |
| 06/23/2004 | EP1429727A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 06/23/2004 | EP1429689A1 Rational drug therapy device and methods |
| 06/23/2004 | EP1429617A2 Methods for sterilizing preparations of digestive enzymes |
| 06/23/2004 | EP1429602A1 Methods for treating disorders using plant extracts |
| 06/23/2004 | EP1353906B1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 06/23/2004 | EP1263932A4 Embryonic stem cells and neural progenitor cells derived therefrom |
| 06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 06/23/2004 | EP1230227B1 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors |
| 06/23/2004 | EP1171573B1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 06/23/2004 | EP1076644B1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 06/23/2004 | EP1071427B1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |